Torrent Pharma Inc C/o,

Torrent Pharma Inc. is a U.S.-based pharmaceutical importer and distributor specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2004, the company operates as a wholly owned subsidiary of Torrent Pharmaceuticals Ltd., a leading Indian pharmaceutical manufacturer. Headquartered in Basking Ridge, New Jersey, Torrent Pharma Inc. plays a pivotal role in introducing and distributing generic pharmaceutical products within the United States market. The company has successfully commercialized 64 FDA-approved generic products, with several achieving significant market shares in their respective therapeutic categories.

Torrent Pharmaceuticals Ltd., the parent company, is renowned for its extensive portfolio across various therapeutic segments, including cardiovascular, central nervous system, gastrointestinal, and women's healthcare. With a presence in over 50 countries, Torrent Pharma Inc. leverages this global network to source and distribute a diverse range of pharmaceutical products in the U.S.

Torrent Pharma Inc. maintains a centralized distribution model from its headquarters in Basking Ridge, New Jersey. This strategic location facilitates efficient logistics and supply chain management, ensuring timely delivery of pharmaceutical products across the United States. The company's distribution network is supported by robust partnerships with third-party logistics providers, enabling it to manage inventory effectively and meet the demands of the U.S. healthcare market. While specific warehouse locations beyond the New Jersey facility are not publicly disclosed, Torrent Pharma Inc.'s operations are designed to optimize distribution efficiency and product availability nationwide.

In the United States pharmaceutical supply chain, Torrent Pharma Inc. functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from its parent company, Torrent Pharmaceuticals Ltd., and other suppliers, the company ensures a steady supply of generic medications to the U.S. market. Torrent Pharma Inc. collaborates with various stakeholders, including wholesalers, healthcare providers, and pharmacies, to facilitate the distribution of its products. This role is crucial in enhancing access to affordable medications and supporting the overall efficiency of the U.S. pharmaceutical supply chain.

Torrent Pharma Inc. exhibits a high degree of supplier concentration, with a total import value of $1.1 million USD from India, comprising 32 shipments of 123 unique formulations. Notably, all imports are sourced from Torrent Pharmaceuticals Ltd., indicating a strategic decision to rely on a single supplier for the majority of its product portfolio. This sourcing strategy may offer benefits such as streamlined logistics, consistent product quality, and favorable pricing terms. However, the lack of diversification introduces potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges within the supplier's facilities. The absence of alternative suppliers could impact Torrent Pharma Inc.'s ability to maintain product availability and meet market demand in such scenarios.

The shipment data reveals a consistent pattern of imports from Torrent Pharmaceuticals Ltd., suggesting a stable and long-term relationship between the two entities. This stability is advantageous for maintaining a reliable supply chain. However, the overreliance on a single supplier underscores the importance of developing contingency plans and exploring opportunities to diversify the supplier base to mitigate potential risks associated with supplier concentration.

Torrent Pharma Inc.'s supply chain resilience is closely tied to the operational stability of Torrent Pharmaceuticals Ltd. The company's reliance on a single supplier for the majority of its product imports means that any disruptions within Torrent Pharmaceuticals Ltd.'s manufacturing facilities could directly affect Torrent Pharma Inc.'s ability to supply products to the U.S. market. While Torrent Pharmaceuticals Ltd. is a reputable manufacturer with a significant global presence, the lack of alternative suppliers introduces vulnerabilities. To enhance supply chain resilience, Torrent Pharma Inc. could consider establishing relationships with additional suppliers, diversifying its product formulations, and developing contingency plans to address potential disruptions. Ensuring that all suppliers comply with FDA regulations and maintain high manufacturing standards is essential for maintaining product quality and regulatory compliance.

Torrent Pharma Inc.'s sourcing pattern, characterized by a high degree of supplier concentration, has strategic implications for its competitive position in the U.S. pharmaceutical market. The strong partnership with Torrent Pharmaceuticals Ltd. allows for favorable terms and a consistent supply of products. However, the overreliance on a single supplier may limit the company's flexibility in responding to market changes, such as shifts in demand or the introduction of new competitors. Diversifying the supplier base could provide Torrent Pharma Inc. with greater leverage in negotiations, access to a broader range of products, and enhanced ability to adapt to market dynamics. For Indian exporters seeking to become alternative suppliers, demonstrating compliance with FDA regulations, maintaining high manufacturing standards, and offering competitive pricing could position them as viable partners for Torrent Pharma Inc.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for the safety, efficacy, and quality of drugs imported into the U.S. Pharmaceutical importers must ensure that their products comply with FDA regulations, including proper labeling, manufacturing practices, and approval status. The FDA's Regulatory Procedures Manual and Investigations Operations Manual provide detailed guidance on import operations and actions.

The FDA's import program aims to protect public health by ensuring that imported drugs meet the same standards as domestically produced drugs. This includes verifying that drugs are not adulterated, misbranded, or unapproved. The FDA examines and analyzes samples of imported drugs to ensure compliance with applicable standards and labeling requirements. Importers are required to file an entry notice and an entry bond with U.S. Customs and Border Protection (CBP), pending a decision regarding the admissibility of the product.

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. All foreign drug establishments whose products are imported into the U.S. must register their establishments with the FDA and list all their drug products in commercial distribution in the United States. This registration ensures that the FDA is notified of all regulated products imported into the U.S. Additionally, imported drugs must comply with Good Manufacturing Practice (GMP) regulations, which are enforced by the FDA to ensure that drugs are produced consistently and controlled to quality standards. GMP compliance is essential for maintaining product quality and safety.

The FDA recognizes GMP certificates from various international standards, including EU GMP, WHO GMP, and PIC/S. These certifications indicate that a manufacturing facility adheres to recognized quality standards. Importers must ensure that their suppliers hold valid GMP certifications to meet FDA requirements. Additionally, importers must obtain wholesale distribution authorization to distribute pharmaceutical products within the United States. This authorization ensures that distributors comply with federal and state regulations governing the distribution of drugs.

Imported pharmaceutical products must meet FDA requirements for quality, safety, and effectiveness. This includes compliance with labeling requirements, which ensure that consumers and healthcare providers have accurate and informative product information. Drug labeling must include the drug's established name, dosage form, strength, and directions for use, among other information. The FDA may review drug labeling at the time the product is offered for import to verify compliance with regulations.

Batch testing and stability requirements are essential to ensure that pharmaceutical products maintain their quality and efficacy throughout their shelf life. Imported drugs must undergo appropriate testing to verify their identity, strength, quality, and purity. Labeling language requirements mandate that labels be in English to ensure that information is accessible to U.S. consumers and healthcare providers. Serialization mandates require that drug products have unique identifiers to facilitate tracking and prevent counterfeit products from entering the supply chain.

Between 2024 and 2026, the FDA has implemented several policy changes affecting the importation of pharmaceutical products into the United States. These changes include updates to the Import for Export (IFE) provisions, which allow for the importation of unapproved drugs intended for further processing and subsequent export. The FDA has also enhanced its import screening processes to improve the efficiency and effectiveness of its import program. These regulatory changes aim to strengthen the integrity of the U.S. pharmaceutical supply chain and ensure that imported drugs meet the necessary standards for quality and safety.

Torrent Pharma Inc.'s product strategy focuses on importing and distributing generic pharmaceutical formulations, with a particular emphasis on cardiovascular and antimalarial & antiparasitic therapeutic categories. The company's portfolio includes products such as Isosorbide and Dapsone, which are essential in the management of cardiovascular conditions and the treatment of malaria and other parasitic infections. The decision to import these specific therapeutic areas aligns with market demand for affordable and effective generic medications in the United States. By